314 related articles for article (PubMed ID: 25592118)
21. [Retina penetration of subconjunctival ranibizumab injection in the rabbit eye].
Zhao Y; Lei W
Zhonghua Yan Ke Za Zhi; 2015 May; 51(5):356-9. PubMed ID: 26311696
[TBL] [Abstract][Full Text] [Related]
22. Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits.
Kim HM; Park YJ; Lee S; Son JY; Hong HK; Ham MH; Jin X; Chung JY; Park KH; Park KD; Woo SJ
Transl Vis Sci Technol; 2020 Mar; 9(4):7. PubMed ID: 32818095
[TBL] [Abstract][Full Text] [Related]
23. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
24. Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model.
Christoforidis JB; Briley K; Binzel K; Bhatia P; Wei L; Kumar K; Knopp MV
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5636-5645. PubMed ID: 29094168
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of HM-3 after intravitreal administration in mice.
Yuan D; Shen H; Yuan S; Liu X; Xia X; Xie P; Li W; Hu J; Liu Q; Xu H
Curr Eye Res; 2014 Aug; 39(8):837-44. PubMed ID: 24559456
[TBL] [Abstract][Full Text] [Related]
26. Injection site and pharmacokinetics after intravitreal injection of immunoglobulin G.
Miura Y; Uematsu M; Teshima M; Suzuma K; Kumagami T; Sasaki H; Kitaoka T
J Ocul Pharmacol Ther; 2011 Feb; 27(1):35-41. PubMed ID: 21182428
[TBL] [Abstract][Full Text] [Related]
27. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
28. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac.
Durairaj C; Kim SJ; Edelhauser HF; Shah JC; Kompella UB
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4887-97. PubMed ID: 19516015
[TBL] [Abstract][Full Text] [Related]
29. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT.
Christoforidis JB; Williams MM; Kothandaraman S; Kumar K; Epitropoulos FJ; Knopp MV
Curr Eye Res; 2012 Dec; 37(12):1171-4. PubMed ID: 22991959
[TBL] [Abstract][Full Text] [Related]
31. Extended Pharmacokinetic Model of the Intravitreal Injections of Macromolecules in Rabbits. Part 2: Parameter Estimation Based on Concentration Dynamics in the Vitreous, Retina, and Aqueous Humor.
Lamminsalo M; Karvinen T; Subrizi A; Urtti A; Ranta VP
Pharm Res; 2020 Oct; 37(11):226. PubMed ID: 33094404
[TBL] [Abstract][Full Text] [Related]
32. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes.
Goldenberg DT; Giblin FJ; Cheng M; Chintala SK; Trese MT; Drenser KA; Ruby AJ
Retina; 2011 Feb; 31(2):393-400. PubMed ID: 21099453
[TBL] [Abstract][Full Text] [Related]
33. Potential of subconjunctival aflibercept in treating choroidal neovascularization.
Nirmal J; Barathi VA; Dickescheid A; Wey YS; Nirmal S; Raja MM; Venkatraman S; Agrawal R
Exp Eye Res; 2020 Oct; 199():108187. PubMed ID: 32795527
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X
Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
36. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
Krohne TU; Eter N; Holz FG; Meyer CH
Am J Ophthalmol; 2008 Oct; 146(4):508-12. PubMed ID: 18635152
[TBL] [Abstract][Full Text] [Related]
37. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit.
Kim MJ; Han ES; Kim J; Kim TW
J Ocul Pharmacol Ther; 2010 Feb; 26(1):49-53. PubMed ID: 20148650
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes.
Gupta SK; Velpandian T; Dhingra N; Jaiswal J
J Ocul Pharmacol Ther; 2000 Dec; 16(6):511-8. PubMed ID: 11132898
[TBL] [Abstract][Full Text] [Related]
39. Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.
Ahn SJ; Hong HK; Na YM; Park SJ; Ahn J; Oh J; Chung JY; Park KH; Woo SJ
J Vis Exp; 2016 Jul; (113):. PubMed ID: 27500363
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
